Search

A study conducted at Bulent Ecevit University in Turkey explored the effectiveness of intragastric botulinum toxin injections as a potential treatment for obesity. The research, which included 67 patients, found that injections in both the gastric antrum and fundus regions led to greater weight loss compared to injections in the antrum alone. The study concluded that these injections could be a safe and effective method for inducing satiety and weight loss in obese individuals, with diet adherence playing a crucial role in the treatment's efficacy. Further research is needed to fully assess the treatment's effectiveness in combating obesity. [Extracted from the article]

Researchers from China Medical University and Hospital have conducted a pilot study on a new approach for treating female underactive bladders with chronic urine retention using a combination of transvaginal ultrasound-guided botulinum toxin A injection and transurethral incision of the bladder neck. The study showed significant improvements in voiding volume, post-void residual urine, voiding efficiency, and a decrease in the need for clean intermittent catheterization. This research provides valuable insights into the surgical treatment of underactive bladders in women. [Extracted from the article]

A recent study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, explored the effects of extracranial injections of Botulinum Toxin Type A on the activation and sensitization of central trigeminovascular neurons. The research focused on the mechanism of action of onabotA in preventing activation and sensitization of dura-sensitive neurons in the spinal trigeminal nucleus. The study found that onabotA was able to prevent activation and sensitization of wide-dynamic range neurons, but had no effect on high-threshold neurons. These findings provide pre-clinical evidence on the potential mechanisms of action of onabotA and other drugs targeting calcitonin gene-related peptide signaling. [Extracted from the article]

A study conducted at the Dr. Gerald Niznick College of Dentistry focused on the use of botulinum toxin A (BTX-A) to treat myofascial pain in patients who did not respond to conservative management. The study involved injecting BTX-A into the masseter and temporalis muscles of 26 patients with masticatory myofascial pain. Results showed a significant positive correlation between BTX-A administration and reductions in pain, improvements in oral function, increased mouth opening, tenderness to palpation, and reduction in facial width. The researchers concluded that BTX-A may be a safe and effective treatment for myofascial pain in patients for whom standard conservative management has been unsuccessful. [Extracted from the article]

A researcher from Tehran University of Medical Sciences has detailed findings on the use of Botulinum Toxin A (BT-A) in treating migraine and non-migraine head pain. BT-A, known for its ability to inhibit acetylcholine release, has shown effectiveness in pain control by inhibiting neurotransmitters associated with pain and inflammation. Studies have demonstrated the beneficial effects of BT-A in treating primary and secondary headache disorders, suggesting its potential for chronic migraine prophylaxis and other headache conditions. [Extracted from the article]

Researchers from the Medical University of Warsaw have published new data on trigeminal neuralgia, a common form of craniofacial pain. The study highlights the efficacy of botulinum toxin type A therapy in alleviating pain for patients with trigeminal neuralgia, offering a potential alternative treatment option. The research provides an overview of trigeminal neuralgia, including its characteristics, etiology, epidemiology, classification, and management, with a focus on the use of botulinum neurotoxin A. [Extracted from the article]

A researcher at Zealand University Hospital has published a new study on the non-cosmetic use of botulinum toxin (BTX) in surgical conditions. BTX is a neurotoxin that can relax muscles and reduce pain sensitization. The study found that BTX is increasingly being used to treat medical and surgical conditions, despite weak evidence and without approval from the European Medicine Agency. The research provides an overview of how BTX is used in different surgical specialties. For more information, the study can be accessed for free through the Scandinavian Journal of Surgery. [Extracted from the article]

A recent study conducted at the University Children's Hospital has explored the use of botulinum toxin (BoNT) in the treatment of gastrointestinal disorders in children. The researchers found that BoNT can be considered for children with achalasia, cricopharyngeal achalasia, delayed gastric emptying, anal achalasia, constipation after Hirschsprung disease corrective surgery, resistant functional constipation, and chronic anal fissure. The study suggests that BoNT may be a viable option for improving surgical outcomes and treating these conditions in selected pediatric patients. Further information on this research can be found in the Journal of Pediatric Gastroenterology and Nutrition. [Extracted from the article]

A recent study conducted at Stellenbosch University in South Africa examined the association between antipsychotic medication use and chronic dystonia, a condition characterized by sustained muscle contractions and abnormal postures. The study found that patients with antipsychotic-induced dystonia tended to present at a younger age, were more likely to be female, required higher doses of Botulinum toxin treatment, and incurred higher treatment costs compared to those with primary dystonia. The research also identified age and Botulinum toxin dose as factors associated with psychotropic-related dystonia. The study provides valuable insights into the demographic and clinical profiles of individuals with dystonia caused by antipsychotic medication, which can inform preventative strategies and improve patient care. [Extracted from the article]

A recent study conducted by Yonsei University College of Dentistry in Seoul, South Korea, examined the immunogenicity of botulinum toxin type A in different clinical and cosmetic treatments. The study found that while the overall incidence of neutralizing antibody formation with botulinum toxin type A treatment is relatively low, it varies depending on the indication and is influenced by factors such as the frequency of injections and the cumulative dose. The research highlights the need for further investigation into antibody formation mechanisms and the development of strategies to minimize their impact on treatment efficacy. For more information, the full article can be accessed through the provided link. [Extracted from the article]

A recent study conducted at Osijek University Hospital Center in Croatia explored the effects of botulinum toxin therapy on eye movements and non-motor symptoms in patients with cervical dystonia (CD). The study found that memory-guided saccades, depression, and anxiety significantly improved after the administration of botulinum toxin type A (BoNT/A). CD is a condition characterized by involuntary activity of cervical muscles and is often accompanied by various non-motor symptoms. This research suggests that BoNT/A may have a central effect on CD and provides valuable insights into the potential benefits of this therapy. [Extracted from the article]

A recent study conducted at the Medical University of Lodz in Poland examined the impact of intravesical onabotulinumtoxinA (Botox) injections on sexual dysfunction in patients with overactive bladder (OAB). The study included 40 sexually active patients with OAB, both men and women, who completed the Sexual Quality of Life questionnaire before treatment and at 3 and 6 months after treatment. The results showed that OAB treatment with onabotulinumtoxinA did not significantly affect the quality of sexual life in either men or women. However, the researchers noted the need for further research using questionnaires specifically designed to assess the sexual life of patients with OAB, particularly in men. [Extracted from the article]

A recent study conducted by researchers at the Catholic University of Korea explores the use of botulinum toxin as a treatment for persistent twitching in the first toe. The study focuses on a case of a male patient in his 30s who experienced unyielding twitching in the sole of his left foot for two years. Traditional pharmacological interventions did not improve his condition, but the administration of botulinum toxin injections resulted in a significant reduction in both the frequency and severity of the twitching. This case study highlights the potential therapeutic benefits of botulinum toxin injections for similar clinical presentations. [Extracted from the article]

A new report from researchers at the Aravind Eye Hospital and Postgraduate Institute of Ophthalmology in Tamil Nadu, India, explores the effectiveness of botulinum toxin A (BTX-A) in treating acute acquired comitant esotropia (AACE) in children and young adolescents. The study found that BTX-A therapy showed efficacy in treating esotropia, with over half of the patients achieving optimal outcomes and improvements in stereopsis and sensory fusion. Early intervention within three months of symptom onset was found to significantly correlate with treatment success. The study highlights the importance of patient-specific considerations and close follow-up to monitor residual and recurrence of esotropia, with surgical intervention potentially increasing the final success rate. [Extracted from the article]

MingMed Biotechnology, a company focused on drug development, has received FDA approval for its Investigational New Drug (IND) application for YY003, the world's first liquid formulation of recombinant Botulinum Toxin Type A (BoNT/A). The liquid formulation, packaged in a pre-filled syringe, is intended for the treatment of glabellar lines. Claruvis Pharmaceutical, a subsidiary of MingMed Biotechnology, has completed Phase III clinical trials for the treatment of medium to severe glabellar lines and has achieved positive results. The company has also started a Phase II clinical trial for the treatment of adult upper arm spasm in China. This approval is seen as a significant milestone in the botulinum toxin market. [Extracted from the article]

A new report discusses research conducted at Istanbul Medeniyet University on the use of botulinum toxin type A to treat tremors in patients with multiple sclerosis (MS). The study included 8 patients who received injections of the toxin and their medical records were reviewed before and after treatment. The results showed significant improvement in tremor scores and hand function after treatment, with no adverse reactions observed. The researchers concluded that botulinum toxin may be an effective treatment option for MS-related tremors, but further studies are needed to confirm these findings. [Extracted from the article]

Researchers at the Federal University of Paraiba in Brazil have reported on a case of trigeminal neuralgia (TN) that was successfully treated with botulinum toxin type A. TN is a headache characterized by intense pain in the facial region, and it can be caused by structural mechanisms such as vascular compression of the trigeminal nerve root. In this case, the patient had TN secondary to basilar invagination (BI) and vascular compression, which had a significant impact on their quality of life. Treatment with botulinum toxin type A was effective in managing the patient's pain. The study highlights the therapeutic success of this treatment in a complex and refractory case of pain syndrome. [Extracted from the article]

This patent application discusses the development of pharmaceutical compositions containing Clostridial toxins, specifically botulinum toxin, for medical applications. The inventors propose a composition that includes a Clostridial toxin active ingredient, along with various excipients such as trehalose, poloxamer 188, polysorbate 20, L-methionine, N-acetyl-cysteine (NAC), and EDTA. These compositions are stable and suitable for injection, and the patent application also includes methods for making them and their potential use in treating depression and cardiac arrhythmia. The application aims to address the challenges associated with formulating and handling Clostridial toxin pharmaceutical compositions. [Extracted from the article]

A recent report from Brussels, Belgium discusses the diagnosis and treatment of chronic giant diaphragmatic hernia, a severe disease. The report presents a case study of a 66-year-old patient with a giant diaphragmatic hernia and a 12-year history of respiratory insufficiency. The researchers used 3D volumetry and botulinum toxin A injection to assess the risk of complications and prepare for surgery. The patient had a successful outcome with no evidence of recurrence. This report highlights the utility of 3D reconstruction and botulinum toxin A in diaphragmatic hernia repair. [Extracted from the article]

A researcher from Tanta University in Egypt has conducted a study on the use of botulinum toxin therapy to manage salivary gland dysfunction caused by radiotherapy. The study involved injecting botulinum toxin into the salivary glands of rats before exposing them to radiation. The results showed that the botulinum-injected glands had better acinar architecture compared to the saline group, indicating that botulinum neurotoxin protected the salivary gland cells from the effects of radiation. This research suggests that botulinum toxin therapy could be an effective treatment for radiotherapy-induced salivary gland dysfunction. [Extracted from the article]

A study conducted by Dongguk University College of Medicine in South Korea examined the effects of administering botulinum neurotoxin A (BoNT/A) at different times after a nerve injury in rats. The study found that immediate administration of BoNT/A after the injury was most effective for nerve regeneration, but administration one week post-injury also significantly enhanced recovery. The levels of certain proteins related to nerve regeneration were higher in the groups that received BoNT/A injections. The study suggests that prompt administration of BoNT/A after nerve damage is beneficial, but administration during the non-acute phase can also be effective. [Extracted from the article]

A recent study conducted at the University of Pisa in Italy examined the long-term management of post-stroke spasticity using botulinum toxin A (BoNT-A) injections. The study analyzed medical records of 95 chronic stroke patients who underwent BoNT-A treatment for spasticity over a period of 2 to 14 years. The findings revealed that the interval between BoNT-A injections increased throughout the treatment duration, and there was a trend of escalating dosage, suggesting a potential rise in the severity of spasticity or changes in treatment response over time. The study emphasizes the need for prompt recognition and management of spasticity post-stroke, as well as the importance of monitoring long-term treatment outcomes. [Extracted from the article]

A recent study conducted at Tzu Chi University in Hualien, Taiwan, examined the use of botulinum toxin A (BoNT-A) injections for the treatment of non-neurogenic dysfunctional voiding (DV) in women. DV is a common condition characterized by voiding dysfunction, and effective treatment options are limited due to its unknown cause. The study found that BoNT-A injections into the urethral sphincter were successful in improving voiding efficiency in 40.9% of women with DV. Factors such as a higher grade of bladder outlet obstruction and a history of pelvic surgery were identified as predictive factors for a successful treatment outcome. [Extracted from the article]

A study conducted by researchers at Fujita Health University in Japan focused on the long-term effects of repeated botulinum toxin A injections on lower limb spasticity and gait function in a 36-year-old woman with right cerebral hemorrhage. The patient received 30 treatments over 12 years, with injections given every 147 days on average. The study found that the injections effectively improved abnormal gait patterns, although certain gait characteristics did not improve after 30 injections. The research suggests that repeated botulinum toxin A injections can be beneficial for improving gait function in certain cases. [Extracted from the article]

A recent study conducted in Detroit, Michigan, explores the use of botulinum toxin A (BoNT-A) in dermatology, specifically in scar formation, rosacea, and antiaging. The study found that while BoNT-A is effective in the short term, more research is needed to understand its long-term effects and the frequency of treatment. In vitro studies have provided evidence of BoNT-A's mechanism of action, but further studies are required to identify its long-term treatment effects. This research provides valuable insights into the potential uses of BoNT-A in dermatology. [Extracted from the article]

A recent report from Boston University highlights the impact of glandular disorders such as sialorrhea, hyperhidrosis, bromhidrosis, and chromhidrosis on patients' health and quality of life. The researchers discuss the use of neuromodulators, specifically botulinum toxin, as a safe and effective treatment option for reducing gland secretions and improving patients' quality of life. While botulinum toxin serotype A is FDA-approved for certain conditions, further research is needed to determine optimal dosing and administration techniques for sialorrhea, bromhidrosis, and chromhidrosis. Overall, neuromodulators show promise in the noninvasive treatment of excess gland activity. [Extracted from the article]

A study conducted at Seoul National University Hospital in South Korea explores the efficacy of botulinum toxin injection for managing abdominal pain in cancer survivors. The study focuses on a case of a cancer survivor in his 70s who experienced recurrent abdominal pain and declined traditional treatment methods due to anxiety. The patient underwent a right-sided unilateral retrocrural single-needle technique, which provided significant and sustained pain relief. The findings highlight the importance of personalized and innovative pain management strategies for cancer survivors with upper abdominal pain. [Extracted from the article]

A recent study conducted by researchers at the University of Evry in France has explored the use of deep learning technology to predict knee and ankle movements after Botulinum Toxin Type A (BTX-A) treatment for spasticity-related gait disorders. The researchers developed a Bidirectional Long Short-Term Memory (Bi-LSTM) deep learning architecture and incorporated categorical medical treatment data into their models. The results showed that their approach outperformed existing methods, with an average prediction root mean squared error of 2.99° for knee kinematics and 2.21° for ankle kinematics. This research provides valuable insights into improving the accuracy of predicting gait patterns after BTX-A treatment. [Extracted from the article]

A recent study conducted by researchers at Thammasat University in Thailand has found that botulinum toxin A (BoNT-A) injection shows promise as an effective therapy for nail psoriasis. The study compared the efficacy of BoNT-A injection, triamcinolone acetonide (TA) injection, topical combination of vitamin D/steroid (VitD/steroid), and placebo in improving nail psoriasis. The results showed that BoNT-A injection led to a 40% reduction in the total target nail psoriasis severity index (NAPSI) score at 24 weeks, with no serious adverse effects reported. The researchers concluded that BoNT-A injection could provide sustained efficacy for up to 6 months with a single injection. [Extracted from the article]

A recent study conducted at Ca'Foncello Hospital in Treviso, Italy, explored the effectiveness of using intramuscular botulinum toxin (BTX-A) as an adjunct to arthrocentesis with viscosupplementation in the management of temporomandibular joint (TMJ) osteoarthritis. The study divided patients into two groups, with one group receiving BTX-A injections and arthrocentesis with viscosupplementation, and the other group receiving only arthrocentesis with viscosupplementation. The study found that the group receiving BTX-A injections experienced greater improvements in clinical outcomes, suggesting that reduced muscle tone and joint load may benefit patients with TMJ osteoarthritis and myofascial pain. Further research is needed to explore this potential treatment option. [Extracted from the article]

A recent systematic review and meta-analysis conducted by researchers at the Royal Free Hospital in London examined the efficacy and safety of intradermal Botulinum toxin A (BTxA) for facial rejuvenation. The study found positive effects of intradermal BTxA on various outcome measures related to facial rejuvenation, including improvements in sebum production, pore size, erythema index, facial wrinkles, skin texture and elasticity, and overall facelift. However, the researchers concluded that more high-quality research is needed to establish definitive conclusions. These findings contribute to the evidence base for nonsurgical aesthetic treatments and highlight the importance of ongoing research in this field. [Extracted from the article]

Researchers from Shahid Beheshti University of Medical Sciences in Tehran, Iran, conducted a pilot study to assess the effect of Botulinum toxin (Masport) injection following internal urethrotomy on patients with urethral stricture. The study involved 28 patients who were divided into intervention and control groups. The researchers found that the group receiving the Masport injection had a better prognosis and showed significant improvement in various measures compared to the control group. The study suggests that further research should be conducted on the use of botox in conjunction with internal urethrotomy for the management of urethral strictures. [Extracted from the article]

A recent study conducted by researchers from the Buddhist Tzu Chi Medical Foundation and Tzu Chi University in Hualien, Taiwan, explored the use of botulinum toxin A (BoNT-A) injections in the treatment of dysfunctional voiding (DV) in women. DV refers to abnormal urethral sphincter activity during voiding in individuals without neurological conditions. The study found that urethral sphincter denervation or reinnervation activity was commonly observed in women with DV. BoNT-A injections into the urethral sphincter provided effective treatment in nearly half of the patients, with mild improvement in urinary flow rate observed in those with reinnervation. However, the improvement was not superior to those without reinnervation. This research sheds light on the potential benefits and limitations of BoNT-A therapy for DV in women. [Extracted from the article]